PUNE, India, Nov. 25, 2016
PUNE, India, Nov. 25, 2016 /PRNewswire-iReach/ -- Non-alcoholic steatohepatitis or NASH is a common term for "silent" liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.
Complete report on Non-Alcoholic Steatohepatitis (NASH) Drugs Market spread across 68 pages providing 4 company profiles and 9 tables and 34 charts is now available at http://www.marketreportsonline.com/518870.html .
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). NASH is also associated with lysosomal acid lipase deficiency. Patients with only steatosis but no fibrosis can progress to NASH. NASH itself can remain asymptomatic for years, or it can progress to cirrhosis and hepatocellular carcinoma. Risk factors such as insulin resistance related to obesity are central to the pathogenesis of NASH. Methods to diagnose NASH include MRI, CT or X-rays, however, only liver biopsy is reliable. There are no approved NASH drugs available in the market, but they are expected to enter the market by 2020. The potential NASH drug candidate include Elafirbranor, OCA, CVC and Aramchol. Currently, off-label drugs and therapies are employed to counter the progression of NASH.
Company Coverage: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics, Inc. & Galmed Pharmaceuticals Ltd.
The global NASH drugs market is expected to experience robust growth post the launch of NASH therapeutic drugs, primarily due to increasing patient base, rise in obese population, increasing number of people suffering from type-2 diabetes coupled with increasing healthcare expenditure. However, the market growth is hindered by the unavailability of effective biomarkers, high cost of drugs and undefined pathogenesis.
The report "Global NASH Drugs Market: Industry Analysis & Outlook (2016-2020)" analyzes the development of this market, with focus on the US and Europe markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.
Purchase a copy of this "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2016-2025)" research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=518870 .
Major Points from Table of Contents:
1.1 Nonalcoholic Steatohepatitis (NASH)
1.2 Causes & Symptoms
2. Global NASH Market
2.1 Global NASH Drugs Market Forecast by Value2.2 Global NASH Drugs Market Forecast by Drug Class2.3 Global NASH Off Label Drugs Market Forecast by Value
3. Global NASH Therapeutics Market
3.1 Global NASH Therapeutics Market Forecast by Value
3.2 Global NASH Therapeutics Market Forecast by Drug Type
3.3 Global NASH Therapeutics Market Forecast by Region
3.4 Global NASH Therapeutics Market by Type
3.4.1 Global Elafibranor Market Forecast by Value
3.4.2 Global Obeticholic Acid (OCA) Market Forecast by Value
3.4.3 Global Obeticholic Acid (OCA) Market Forecast by Region
3.4.4 Global Cenicriviroc (CVC) Market Forecast by Value
3.4.5 Global Cenicriviroc (CVC) Market Forecast by Region
3.4.6 Global Aramchol Market Forecast by Value
4. Regional NASH Market
4.1 The US4.1.1 The US NASH Therapeutics Market Forecast by Value4.1.2 The US NASH Therapeutics Market Forecast by Drug Type4.2 The Europe4.2.1 The Europe NASH Therapeutics Market Forecast by Value4.3 ROW4.3.1 ROW NASH Therapeutics Market Forecast by Value
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Patient Base
5.1.2 Increasing Population with Type-2 Diabetes
5.1.3 Escalating Obese Population
5.1.4 Rising Healthcare Expenditure
5.1.5 Increasing GDP Per Capita
5.2.1 Development of NASH Diagnosis Methods and Biomarkers
5.2.2 Strong Research and Development Efforts by Companies
5.3.1 Absence of Cheap and Effective Diagnostics
5.3.2 Regulatory Challenge and Undefined Pathogenesis
5.3.3 Costly NASH Therapeutics
6. Competitive Landscape
6.1 Revenue and Market Cap6.2 Major Pipeline Products
7. Company Profiles
Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html .
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
Media Contact: Ritesh Tiwari, Market Reports Online, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Market Reports OnlinePR Newswire
Last updated on: 25/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.